

Supplementary Table 3

A

Cell line	EC50 (μM SMAP)	EC50 (μM Cisplatin)
OV78	19.66	50.13
OV82	15.05	15.14
OV84	15.12	∞
OV93	19.12	17.18
OV85	23.3	∞
OV145	11.57	115

B

Cell line	EC50 (μM SMAP)	EC50 (μM Cisplatin)	IC50 (μM Olaparib)	EC50 (μM SMAP + Olaparib)
OV81	11.39	5.89	131.3	5.95
OV81-CP40	11.53	46.57	154.2	8.94
PEO-1	10.83	4.18	51.85	5.14
PEO-C4.2	8.41	5.51	108.8	6.71

C

Cell line	EC50 (μM SMAP + Cisplatin)	Combination Index (CI)
OV81	19.9	5.1
PEO-1	1.77	0.6
PEO-C4.2	14.4	4.3

Supplementary Table 3 – **SMAP-061, Cisplatin and Olaparib** calculated EC₅₀ and IC₅₀ values for **HGSC primary cell lines**. A) EC₅₀ values of patient derived cell lines calculated from the cell viability assays executed in Fig.2A. B) EC₅₀ and IC₅₀ values of patient derived cell lines calculated from the cell viability assays conducted in Fig.2B, Fig.4C and 4D. C) EC₅₀ values of patient derived cell lines calculated from the cell viability isobologram assays performed in Fig.S3.